Saccharomyces boulardii in childhood

被引:67
|
作者
Vandenplas, Yvan [1 ]
Brunser, Oscar [2 ]
Szajewska, Hania [3 ]
机构
[1] Vrije Univ Brussel, Univ Ziekenhuis Kinderen Brussel, B-1090 Brussels, Belgium
[2] Univ Chile, Inst Nutr & Food Technol INTA, Santiago, Chile
[3] Med Univ Warsaw, Warsaw, Poland
关键词
Child; Diarrhea; Gastroenteritis; Probiotic; Saccharomyces boulardii; Yeast; ANTIBIOTIC-ASSOCIATED DIARRHEA; DIFFICILE-ASSOCIATED DIARRHEA; RAT SMALL-INTESTINE; CLOSTRIDIUM-DIFFICILE; HELICOBACTER-PYLORI; RISK-FACTORS; BACTERIAL TRANSLOCATION; ENDOLUMINAL RELEASE; CEREVISIAE FUNGEMIA; CHILDREN;
D O I
10.1007/s00431-008-0879-7
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Probiotics are live microorganisms which confer a health benefit on the host. Saccharomyces boulardii, a yeast, has been found to be an effective probiotic in double-blind placebo-controlled randomized clinical studies. We reviewed the established mechanisms of actions and clinical efficacy in children of S. boulardii. The mechanisms of action of S. boulardii depend mainly on the inhibition of some bacterial toxins, anti-inflammatory effects, and on stimulating effects on the intestinal mucosa such as trophic effects on the brush border enzymes and immunostimulatory effects. At present, in pediatric populations, there is evidence that S. boulardii is beneficial for the treatment of acute gastroenteritis and the prevention of antibiotic-associated diarrhea. More data are needed in other indications such as traveller's diarrhea, Helicobacter pylori eradication, and inflammatory bowel disease. S. boulardii is a yeast strain that has been extensively studied in vitro and in vivo. Recent data have opened the door for new therapeutic indications.
引用
收藏
页码:253 / 265
页数:13
相关论文
共 50 条
  • [21] Saccharomyces boulardii verhindert ein Rezidiv
    P. Stiefelhagen
    MMW - Fortschritte der Medizin, 2010, 152 (44) : 24 - 24
  • [22] Septic shock due to Saccharomyces boulardii
    Ellouze, O.
    Berthoud, V.
    Mervant, M.
    Parthiot, J. P.
    Girard, C.
    MEDECINE ET MALADIES INFECTIEUSES, 2016, 46 (02): : 104 - 105
  • [23] Efficacy and Safety of Saccharomyces boulardii in Acute Childhood Diarrhea: A Double Blind Randomised Controlled Trial
    Riaz, Musheer
    Alam, Seema
    Malik, Abida
    Ali, S. Manazir
    INDIAN JOURNAL OF PEDIATRICS, 2012, 79 (04): : 478 - 482
  • [24] Saccharomyces boulardii effects on gastrointestinal diseases
    Zanello, Galliano
    Meurens, Francois
    Berri, Mustapha
    Salmon, Henri
    CURRENT ISSUES IN MOLECULAR BIOLOGY, 2009, 11 : 47 - 58
  • [25] Effects of Saccharomyces boulardii on Intestinal Mucosa
    Jean-Paul Buts
    Nadine De Keyser
    Digestive Diseases and Sciences, 2006, 51 : 1485 - 1492
  • [26] Recent advances in Saccharomyces boulardii research
    Im, E.
    Pothoulakis, C.
    GASTROENTEROLOGIE CLINIQUE ET BIOLOGIQUE, 2010, 34 : S62 - S70
  • [27] Molecular and physiological comparisons between Saccharomyces cerevisiae and Saccharomyces boulardii
    Fietto, JLR
    Araújo, RS
    Valadao, FN
    Fietto, LG
    Brandao, RL
    Neves, MJ
    Gomes, FCO
    Nicoli, JR
    Castro, IM
    CANADIAN JOURNAL OF MICROBIOLOGY, 2004, 50 (08) : 615 - 621
  • [28] Saccharomyces cerevisiae fungemia in a neutropenic patient treated with Saccharomyces boulardii
    Cesaro, S
    Chinello, P
    Rossi, L
    Zanesco, L
    SUPPORTIVE CARE IN CANCER, 2000, 8 (06) : 504 - 505
  • [29] Saccharomyces fungemia complicating Saccharomyces boulardii treatment in a nonimmunocompromised host
    Rijnders, BJA
    Van Wijngaerden, E
    Verwaest, C
    Peetermans, WE
    INTENSIVE CARE MEDICINE, 2000, 26 (06) : 825 - 825
  • [30] Saccharomyces cerevisiae fungemia in a neutropenic patient treated with Saccharomyces boulardii
    S. Cesaro
    Pierangelo Chinello
    Lucia Rossi
    Luigi Zanesco
    Supportive Care in Cancer, 2000, 8 : 504 - 505